J&J Reports Additional Deaths in Heart Drug Study
Posted on: Wednesday, 4 January 2006, 18:00 CST
Johnson & Johnson subsidiary Scios has reported to the FDA details of two additional deaths in its long-term study of the heart failure drug Natrecor. The deaths occurred within 30 days of the patients taking the drug but were not known about when results from the study were published in October 2005.
The study compares Natrecor with placebo in order to gauge the risk profile of the drug. The new findings may exacerbate recent safety concerns around the drug, which was approved for the treatment of acute heart failure in 2001.
The company will now re-analyze the data in light of the new findings to see if the difference now reaches statistical significance, however the company said in a statement that it is "confident these two additional cases have no impact on the overall benefit/risk profile of Natrecor when prescribed according to the approved label."
In January 2005, Scios agreed with the FDA to conduct an expanded analysis to evaluate all-cause mortality through 180 days following treatment with Natrecor or placebo. This expanded analysis goes beyond the study's original protocol defined 30-day mortality follow-up period.
It was in the course of conducting this expanded analysis that the two additional deaths at 30 days post treatment were identified. A final report of this expanded analysis is planned for submission to FDA, as well as to relevant health authorities in other countries, in the first quarter of 2006.
Source: Datamonitor
Related Articles
- Understand the Neurological Diagnostic Biomarkers Which Could Expand Drug Revenues and Prove Useful in the Early Detection of Certain Diseases
- Crystallize Your Business Decisions With Drug Approval Trends at the FDA and EMEA Report
- 'Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- And Prostate Cancer' Provides a Framework and a Careful Evaluation of Drug Candidates, Technologies and Competitors
- ITI Initiates Phase II Study of Insomnia Drug
- Drug Eluting Balloons Show Promise As a Potential Alternative to Drug Eluting Stents Used in the Treatment of Coronary Artery Disease
- The Most Efficient Way to Get Your Food and Drug Products to Market Within FDA Regulations
- Joining Forces, Two Drug Firms Develop a Once-a-Day AIDS Pill ; FDA Approval Expected By the End of the Year
- Single-Day Famvir Treatment Found to Shorten the Duration of Recurrent Genital Herpes Outbreaks
- UCB Receives FDA Orphan Drug Designation for Brivaracetam for the Treatment of Symptomatic Myoclonus
- Cardiologist: Stop Marketing of Heart Drug Natrecor
 |
 |
User Comments (0)
RSS Feeds